Company news

Spero Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Spero Therapeutics Announces Fourth Quarter and Full-Year 2019 Operating Results and Provides Pipeline Update

March 15, 2020

Spero Therapeutics Receives FDA Orphan Drug Designation for SPR720 for the Treatment of Nontuberculous Mycobacterial (NTM) Infection

March 10, 2020

Spero Therapeutics Announces Closing of Rights Offering

March 4, 2020

Spero Therapeutics Announces Commencement of Rights Offering

February 10, 2020

Spero Therapeutics Announces Exercise of $15.9 Million Option by BARDA for Tebipenem HBr Development

February 4, 2020

Spero Therapeutics Announces Proposed Rights Offering

January 29, 2020

Spero Reports Preliminary Findings from Phase 1 Clinical Trial of SPR206 and Plans to Advance Program with Alliance Partners Everest Medicines and the Department of Defense

January 12, 2020

Spero Reports Preliminary Findings from Phase 1 Clinical Trial of SPR720 and Announces Plans to Advance Program into Proof-of-Concept Clinical Trial in Patients with NTM Pulmonary Disease

December 3, 2019

Spero Therapeutics to Host Key Opinion Leader Symposium in December

November 25, 2019

Spero Therapeutics Announces Third Quarter 2019 Operating Results and Provides Pipeline Review

November 3, 2019

Spero Therapeutics Announces Positive Recommendation to Continue Phase 3 Clinical Trial of SPR994 as Planned Following Independent Review Committee Analysis of SPR994 Treated Patients in Lead-in Cohort of Trial

October 2, 2019

Spero Therapeutics Announces Presentations at IDWeek 2019

September 25, 2019

← Newer news releases

Calls

The 5 newest of 16 calls. Every call is listed under its year.

Decks

The 5 newest of 19 decks. Every deck is listed under its year.